Warfarin treatment after coronary stenting was associated with an increased risk of the primary composite endpoint (OR 1.7; 95% CI 1.0-3.0; P=0.05) and major bleeding.
Cohort
Yes
Does combined antiplatelet-warfarin therapy improve ischemic outcomes and safety in patients requiring long-term anticoagulation after coronary stenting?
In patients undergoing PCI, long-term warfarin therapy combined with antiplatelets is associated with increased risks of both ischemic events and major bleeding compared to matched controls.
Effect estimate: OR 1.7 (95% CI 1.0-3.0)
p-value: p=0.05
AIM: The aim of this study was to evaluate the antithrombotic treatment adopted after coronary stenting in patients requiring long-term anticoagulation. METHODS AND RESULTS: We analysed retrospectively all consecutive patients on warfarin therapy (n = 239, mean age 70 years, men 74%) who underwent percutaneous coronary intervention (PCI) in 2003-04 in six hospitals. An age- and sex-matched control group with similar disease presentation (unstable or stable symptoms) was selected from the study period. Primary endpoint was defined as the occurrence of death, myocardial infarction, target vessel revascularization, or stent thrombosis at 12 months. Warfarin treatment was an independent predictor of both primary endpoint (OR 1.7, 95% CI 1.0-3.0, P = 0.05) and major bleeding (OR 3.4, 95% CI 1.2-9.3, P = 0.02). Triple therapy with aspirin and clopidogrel was the most common (48%) option in stented patients in warfarin group, and there was a significant (P = 0.004) difference between the drug combinations in stent thrombosis with the highest (15.2%) incidence in patients receiving warfarin plus aspirin combination. CONCLUSION: Our study shows that the prognosis is unsatisfactory in warfarin-treated patients irrespective of the drug combination used. Aspirin plus warfarin combination seems to be inadequate to prevent stent thrombosis.
Karjalainen et al. (Sat,) conducted a cohort in Coronary stenting in patients requiring long-term anticoagulation. Warfarin therapy vs. Age- and sex-matched control group was evaluated on Occurrence of death, myocardial infarction, target vessel revascularization, or stent thrombosis at 12 months (OR 1.7, 95% CI 1.0-3.0, p=0.05). Warfarin treatment after coronary stenting was associated with an increased risk of the primary composite endpoint (OR 1.7; 95% CI 1.0-3.0; P=0.05) and major bleeding.